Literature DB >> 9118515

Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.

G P Rossi1, A Sacchetto, E Pavan, P Palatini, G R Graniero, C Canali, A C Pessina.   

Abstract

BACKGROUND: Since hyperaldosteronism has been experimentally related to myocardial interstitial fibrosis, we investigated the effects of hypertension and excess aldosterone due to aldosterone-producing adenomas (APAs) on the heart. METHODS AND
RESULTS: In 52 hypertensive individuals, we performed Doppler echocardiography for estimation of left ventricular (LV) wall thickness and dimensions, transmitral LV filling flow velocity indexes, and 24-hour ambulatory blood pressure monitoring. Consecutive patients with APAs (n = 26) and essential hypertension (EH, n = 26) were individually matched for age, sex, race, body mass index, casual blood pressure, and known duration of hypertension. The matched groups were similar for demography, casual and 24-hour blood pressure values and variability, and duration of hypertension but differed for serum potassium, plasma renin activity, and aldosterone levels (all P < .001). A thicker interventricular septum (P = .015) and posterior wall (P = .009) and a higher LV mass index (118 +/- 5 versus 100 +/- 4 g/m2, P = .009) were observed in APA compared with EH patients. Both septum and posterior wall thicknesses had a significant direct relationship with age, plasma aldosterone, and mean blood pressure. The integral of the early diastolic filling wave (Ei) (P = .011) and the ratio Ei/Ai (A wave integral) (P = .038) were lower and the atrial contribution to LV filling was higher (52 +/- 2% versus 46 +/- 2%, P = .038) in APA than in EH patients. The ratio Ei/Ai was significantly (P = .008) inversely related only to age and plasma aldosterone.
CONCLUSIONS: In APA patients, the excess aldosterone is associated with both increased LV wall thickness and mass and decreased early diastolic LV filling indexes compared with demographically similar EH with superimposable blood pressure values, profile, and variability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118515     DOI: 10.1161/01.cir.95.6.1471

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  38 in total

1.  CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis.

Authors:  Xu Li; Ying Meng; Xi-Shan Yang; Ping-Sheng Wu; Shu-Mei Li; Wen-Yan Lai
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.

Authors:  Emmanuel L Bravo
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 3.  Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

4.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

Review 5.  Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.

Authors:  Pierpaolo Pellicori; Concetta Torromeo; Angela Calicchia; Alessandra Ruffa; Martina Di Iorio; John G F Cleland; Manuela Merli
Journal:  Clin Res Cardiol       Date:  2013-09-01       Impact factor: 5.460

Review 6.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

7.  Cardiac remodeling in patients with primary aldosteronism.

Authors:  F Galetta; G Bernini; F Franzoni; A Bacca; I Fivizzani; L Tocchini; M Bernini; P Fallahi; A Antonelli; G Santoro
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

8.  Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment.

Authors:  G Bernini; A Bacca; V Carli; D Carrara; G Materazzi; P Berti; P Miccoli; R Pisano; V Tantardini; M Bernini; S Taddei
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

Review 9.  The ubiquitous mineralocorticoid receptor: clinical implications.

Authors:  Urseline A Hawkins; Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.